SciELO - Scientific Electronic Library Online

 
vol.49 issue3Characterization of snakebite cases attended by the drug and poison research and information center ( CIEMTO) in Medellin, Colombia during 2016Economic costs of acute respiratory infection in a municipality of Colombia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la Universidad Industrial de Santander. Salud

Print version ISSN 0121-0807

Abstract

HENAO Z, Yuly; BOTERO S, Piedad L; PARRADO F, Ilsa Y  and  AMARILES, Pedro. Concordance in the use of teriparatide or zoledronic acid in patients with osteoporosis with international recommendations, in a health company of Colombia. Rev. Univ. Ind. Santander. Salud [online]. 2017, vol.49, n.3, pp.458-468. ISSN 0121-0807.  http://dx.doi.org/10.18273/revsal.v49n3-2017004.

Introduction:

Bisphosphonates are the first-line treatment of osteoporosis in which zoledronate is the most effective. Teriparatide (anabolic agent), due to high cost, should be restricted to the treatment of the most affected patients and after adequate treatment with bisphosphonates.

Objective:

To establish the percentage of patients with osteoporosis, in treatment with teriparatide or zoledronic acid in Colombia, that meet international organizations recommendations.

Method:

Retrospective drug utilization study, January 2012-December 2015, in patients with osteoporosis and treatment with teriparatide or zoledronic acid. The socio-demographic and clinical information and the degree of concordance of teriparatide or zoledronic acid use with recommendations from three international clinical guidelines were reviewed: National Osteoporosis Foundation, National Institute for Health and Clinical Excellence, and Scottish Intercollegiate Guidelines Network.

Results:

103 patients were included, average age in years (standard deviation) 78 (10.4), 74.8% women. Postmenopausal osteoporosis (61.2%) and unspecified osteoporosis (20.4%), both with or without pathological fracture, were the main diagnoses. In 36.9%, the use of teriparatide and zoledronic acid was accord with the guidelines recommendations revised. The use of these drugs in diagnoses different to postmenopausal osteoporosis (43.7%) or initial pharmacotherapy (36.9%) were the main causes for concordance absence.

Conclusions:

Only 36.9% of the reviewed cases, the use of teriparatide or zoledronic acid was accord with international organizations guideliness. Concordance absence is due especially both to the use in diagnoses different to postmenopausal osteoporosis and initial pharmacotherapy.

Keywords : osteoporosis; teriparatide; bone density conservation agents; drug utilization; pharmacoepidemiology.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )